Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06888271 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death

Study acronym: ANDROMEDA
StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 24, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 1 wordv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to evaluate if there are differences in DNA methylation of peripheral blood in patients with Brugada syndrome and healthy subjects. The main question it aims to answer is: Does DNA methylation changes distinguish Brugada patients from healthy controls? Does DNA methylation changes distinguish Brugada patients with high versus low risk of sudden cardiac death?
Trial Details
NCT Number NCT06888271
Lead Sponsor University of Campania Luigi Vanvitelli
Conditions
(from sponsor)		 Brugada Syndrome, Sudden Cardiac Death Due to Cardiac Arrhythmia
Related terms Brugada Syndrome, Death, Sudden, Cardiac
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov